JOP20150319B1 - معقدات دوائية إشعاعية - Google Patents

معقدات دوائية إشعاعية

Info

Publication number
JOP20150319B1
JOP20150319B1 JOP/2015/0319A JOP20150319A JOP20150319B1 JO P20150319 B1 JOP20150319 B1 JO P20150319B1 JO P20150319 A JOP20150319 A JO P20150319A JO P20150319 B1 JOP20150319 B1 JO P20150319B1
Authority
JO
Jordan
Prior art keywords
tissue
targeting
complex
coupling
thorium
Prior art date
Application number
JOP/2015/0319A
Other languages
English (en)
Inventor
Cuthbertson Alan
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54884033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20150319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer As filed Critical Bayer As
Application granted granted Critical
Publication of JOP20150319B1 publication Critical patent/JOP20150319B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

يوفر الاختراع طريقة لتشكيل معقد thorium يستهدف نسيج، تشتمل الطريقة المذكورة على: (أandzwnj;) تشكيل مادة كُلابية octadentate تشمل أربعة أشطُر hydroxypyridinone (HOPO)، مستبدلة في الموضع N مع مجموعة C1-C3 alkyl، وشطر اقتران ينتهي بمجموعة carboxylic acid؛ (بandzwnj;) اقتران المادة الكُلابية octadentate المذكورة مع ببتيد أو بروتين يستهدف نسيج واحد على الأقل يشمل شطر amine واحد على الأقل بواسطة عامل كاشف لاقتران amide واحد على الأقل بهذه الطريقة لتوليد مادة كُلابية تستهدف نسيج؛ و (جـ) اتصال المادة الكُلابية المستهدفة النسيج المذكورة مع محلول مائي يشمل أيون من نظير thorium يبعث alpha واحد على الأقل. تتوافر أيضا طريقة لمعالجة مرض ورمي أو مرض فرط تنسج تشمل إعطاء معقد thorium المستهدف النسيج هذا، بالإضافة إلى توفير المعقد والصياغات الدوائية المقابلة أيضا.
JOP/2015/0319A 2014-12-17 2015-12-16 معقدات دوائية إشعاعية JOP20150319B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422512 2014-12-17

Publications (1)

Publication Number Publication Date
JOP20150319B1 true JOP20150319B1 (ar) 2021-08-17

Family

ID=54884033

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0319A JOP20150319B1 (ar) 2014-12-17 2015-12-16 معقدات دوائية إشعاعية

Country Status (30)

Country Link
US (2) US20170340759A1 (ar)
EP (1) EP3233137A1 (ar)
JP (2) JP6821569B2 (ar)
KR (1) KR20170094223A (ar)
CN (1) CN107278155B (ar)
AR (1) AR103063A1 (ar)
AU (2) AU2015367722A1 (ar)
BR (1) BR112017012841A2 (ar)
CA (1) CA2970841A1 (ar)
CL (1) CL2017001592A1 (ar)
CO (1) CO2017005975A2 (ar)
CR (1) CR20170256A (ar)
CU (1) CU24493B1 (ar)
DO (1) DOP2017000143A (ar)
EA (1) EA201791350A9 (ar)
EC (1) ECSP17038089A (ar)
IL (1) IL252244B (ar)
JO (1) JOP20150319B1 (ar)
MA (1) MA41176A (ar)
MX (1) MX2017008093A (ar)
MY (1) MY194190A (ar)
NI (1) NI201700076A (ar)
PE (2) PE20171181A1 (ar)
PH (1) PH12017501125A1 (ar)
SG (1) SG11201704917XA (ar)
TN (1) TN2017000255A1 (ar)
TW (1) TWI654179B (ar)
UA (1) UA125369C2 (ar)
UY (1) UY36453A (ar)
WO (1) WO2016096843A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017239018A1 (en) * 2016-03-24 2018-08-16 Bayer As Radio-pharmaceutical complexes
SG11201810967VA (en) * 2016-06-10 2019-01-30 Bayer Pharma AG Radio-pharmaceutical complexes
EP3585436A1 (en) * 2017-02-24 2020-01-01 Bayer AS Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN110573186A (zh) * 2017-03-30 2019-12-13 康奈尔大学 发射α的放射性核素的大环配合物及其在癌症的靶向放射治疗中的应用
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
EP3927374A1 (en) 2019-02-21 2021-12-29 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
AU2022210371A1 (en) 2021-01-22 2023-07-20 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104662A2 (en) * 2007-01-11 2009-09-30 GE Healthcare AS Chelating agents
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
CR20170256A (es) 2017-08-11
TN2017000255A1 (en) 2018-10-19
ECSP17038089A (es) 2017-07-31
US20210322583A1 (en) 2021-10-21
BR112017012841A2 (pt) 2018-04-10
CL2017001592A1 (es) 2018-03-16
PE20230829A1 (es) 2023-05-19
TWI654179B (zh) 2019-03-21
MY194190A (en) 2022-11-18
UY36453A (es) 2016-07-29
CO2017005975A2 (es) 2017-11-30
TW201627286A (zh) 2016-08-01
SG11201704917XA (en) 2017-07-28
IL252244A0 (en) 2017-07-31
AR103063A1 (es) 2017-04-12
EP3233137A1 (en) 2017-10-25
DOP2017000143A (es) 2017-07-15
PH12017501125A1 (en) 2017-11-27
CA2970841A1 (en) 2016-06-23
UA125369C2 (uk) 2022-03-02
AU2021202665A1 (en) 2021-05-27
IL252244B (en) 2020-10-29
CU24493B1 (es) 2020-12-17
CU20170082A7 (es) 2017-10-05
MA41176A (fr) 2017-10-24
KR20170094223A (ko) 2017-08-17
WO2016096843A1 (en) 2016-06-23
NI201700076A (es) 2017-09-22
US20170340759A1 (en) 2017-11-30
EA201791350A9 (ru) 2020-02-11
CN107278155A (zh) 2017-10-20
JP2021063108A (ja) 2021-04-22
CN107278155B (zh) 2021-03-30
AU2021202665B2 (en) 2023-04-27
PE20171181A1 (es) 2017-08-22
JP6821569B2 (ja) 2021-01-27
MX2017008093A (es) 2018-02-09
JP7160961B2 (ja) 2022-10-25
JP2018506513A (ja) 2018-03-08
AU2015367722A1 (en) 2017-06-08
EA201791350A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
PH12018502605A1 (en) Radio-pharmaceutical complexes
JOP20150319B1 (ar) معقدات دوائية إشعاعية
MY195681A (en) Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
MX370723B (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía.
MX2017003121A (es) Formulaciones de anticuerpos.
EA201990093A1 (ru) Двухкомпонентная композиция
JOP20170072B1 (ar) معقدات صيدلية مشعة
CY1121264T1 (el) Εστερες στεροειδικης λακταμης και παραγωγα αμφι(2-χλωροαιθυλ)-αμινοφαινοξυ-προπανοϊκου οξεος
UA96243U (uk) Тест-засіб для ідентифікації компонентів екстемпоральних лікарських засобів на основі фільтрувального паперу, модифікованого хромогенним реагентом заліза (ііі) хлоридом
PH22015000456U1 (en) METHOD OF PREPARING TILAPIA (Oreochromis spp) SPREAD
NZ743656A (en) Methods of treating a tauopathy
MY194760A (en) Methods and Systems Employing a Sulfonated Iminodiacetic Acid During Subterranean Treatment Operations